G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients.

ABSTRACT:

Background

The incidence of malaria in the Americas has decreased markedly in recent years. Honduras and the other countries of Mesoamerica and the island of Hispaniola have set the goal of eliminating native malaria by the year 2020. To achieve this goal, Honduras has recently approved national regulations to expand the possibilities of a shortened double dose primaquine (PQ) treatment for vivax malaria. Considering this new shortened anti-malarial treatment, the high frequency of G6PDd genotypes in Honduras, and the lack of routinely assessment of the G6PD deficiency status, this study aimed at investigating the potential association between the intake of PQ and haemolysis in malaria-infected G6PDd subjects.

Methods

This was a prospective cohort and open-label study. Parti

SUBMITTER: Avalos S 

PROVIDER: S-EPMC6225638 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature